Tweet
Sunday Business Post
By Eamon Quinn, business editor
Elan confident of Alzheimer's breakthrough
"Elan's head of global research, Lars Ekman, has spoken of his confidence of a potential early breakthrough in its trials into Alz's disease.
"Elan is conducting two so called Phase 11 trials with drugs giant Wye into AAB-001 treatment which is seeking not only to control but also to reverse the devasting memory loss which the disease wreaks on patients.
"Elan in the past has said that important data signals from the trias would be ready in early part of 2007.
"But in an interview with the Sunday Business Post, Ekman said that the results coulc be delivered as early at this year.
"'I am very enthusiastic for two reasons,' Ekman said. 'First because of the unmet need and second as a scientist I am driven by data. When you have strong data in animal models which is then confirmed in man then your confidence goes up. We have been in clinical trials for about two and half years'.
"Meanwhile, Elan is waiting for clearance from the US FDA next mth on whether it can resume sales of this Multible sclerosis drug Ty. A year ago Elan shares collapsed....
"On Alzmr's, Ekman said the was "Confident" about the coutcome of the trials ointo AAB-001 programme. 'I have never been more intrigued by any programme I have been involved in, including Ty, over the last 25yrs' he said.
"Industry estimates suggest that 12 million patients in western countries have Alzmrs. In the US, the cost of treating 4.5 million patients have been estimated at $100 billion a year"
On the front pages of Money & Markets
By Eamon Quinn, business editor
Elan confident of Alzheimer's breakthrough
"Elan's head of global research, Lars Ekman, has spoken of his confidence of a potential early breakthrough in its trials into Alz's disease.
"Elan is conducting two so called Phase 11 trials with drugs giant Wye into AAB-001 treatment which is seeking not only to control but also to reverse the devasting memory loss which the disease wreaks on patients.
"Elan in the past has said that important data signals from the trias would be ready in early part of 2007.
"But in an interview with the Sunday Business Post, Ekman said that the results coulc be delivered as early at this year.
"'I am very enthusiastic for two reasons,' Ekman said. 'First because of the unmet need and second as a scientist I am driven by data. When you have strong data in animal models which is then confirmed in man then your confidence goes up. We have been in clinical trials for about two and half years'.
"Meanwhile, Elan is waiting for clearance from the US FDA next mth on whether it can resume sales of this Multible sclerosis drug Ty. A year ago Elan shares collapsed....
"On Alzmr's, Ekman said the was "Confident" about the coutcome of the trials ointo AAB-001 programme. 'I have never been more intrigued by any programme I have been involved in, including Ty, over the last 25yrs' he said.
"Industry estimates suggest that 12 million patients in western countries have Alzmrs. In the US, the cost of treating 4.5 million patients have been estimated at $100 billion a year"
On the front pages of Money & Markets
Comment